New approaches to developing antidepressants by enhancing monoaminergic neurotransmission

Expert Opinion on Investigational Drugs

Volumn 12, Issue 4, 2003, Pages 531-543

  Bymaster, Frank P ^a   McNamara, Robert K ^a   Tran, Pierre V ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Dopamine; Dual uptake inhibitors; Major depressive disorder; Monoamine oxidase inhibitors; Noradrenaline; Re uptake inhibitors; Selective serotonin re uptake inhibitors; Serotonin

Indexed keywords

ANTIDEPRESSANT AGENT; ATOMOXETINE; CITALOPRAM; DESIPRAMINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; LU 43706; LY 367265; MILNACIPRAN; MIRTAZAPINE; MONOAMINE; MONOAMINE OXIDASE INHIBITOR; NAFENODONE; NEFAZODONE; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; NORTRIPTYLINE; OPC 14523; PAROXETINE; PLACEBO; REBOXETINE; S 33005; S 34324; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE; VILAZODONE;

CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG STRUCTURE; DYSURIA; HEADACHE; HUMAN; HYPOTHESIS; INSOMNIA; MAJOR DEPRESSION; MONOAMINERGIC SYSTEM; NAUSEA; NEUROCHEMISTRY; NEUROTRANSMISSION; NONHUMAN; PATIENT CARE; PROTEIN DEFICIENCY; RAT; REVIEW; SEXUAL DYSFUNCTION; SOMNOLENCE; SWEATING; SYMPTOM; TREATMENT OUTCOME; XEROSTOMIA;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; ANTIDEPRESSIVE AGENTS; BIOGENIC MONOAMINES; DEPRESSIVE DISORDER, MAJOR; DOPAMINE AGONISTS; HUMANS; SEROTONIN AGONISTS; SEROTONIN UPTAKE INHIBITORS;

EID: 0037396872     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.12.4.531     Document Type: Review

References (130)

1. KESSLER RC, MCGONAGLE KA, ZHOA S et al.: Lifetime and 12 month prevalence of DSMIII-R psychiatric din the United States. Results from the National Comorbidity Survey. Arch. Gen. Psychiatry (1994) 51:8-19.
2. LEPINE JP, GASTPAR M, MENDLEWICZ J et al.: Depression in the community: the first pan-European study DEPRES (Depression Research in European Society). Int. Clin. Psychopharmacol. (1997) 12:19-29.
3. The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020. CJL Murray, AD Lopez (Eds), Harvard University Press, Cambridge, MA, USA (1996).
4. GREDEN JF: The burden of disease for treatment-resistant depression. J. Clin. Psychiatry (2001) 62:26-31.
5. DAVIDSON JR, MELTZER-BRODY SE: The underrecognition and undertreatment of depression: what is the breadth and depth of the problem? J. Clin. Psychiatry (1999) 60:4-9.
6. ROSENBAUM JF, HYLAN TR: Costs of depressive disorders: A review. In: Depressive Disorders (Vol. 1). M Maj, N Sartorius (Eds). John Wiley & Sons Ltd (1999):401-449.
7. GUMNICK JF, NEMEROFF CB: Problems with currently available antidepressants. J. Clin. Psychiatry (2000) 61:5-15.
8. FRAZER A: Pharmacology of antidepressants. J. Clin. Psychopharmacol. (1997) 17(Suppl. 1):2S-18S.
9. CULPEPPER L: Early onset of antidepressant actions: impact on primary care. J. Clin. Psychiatry (2001) 62:4-6.
10. FAWCETT J, BARKIN RL: Efficacy issues with antidepressants. J. Clin. Psychiatry (1997) 58(Suppl. 6):32-39.
11. THASE ME, ENTSUAH R, RUDOLPH RL: Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br. J. Psychiatry (2001) 178:234-241.
12. CHARNEY DS: Monoamine dysfunction and the pathophysiology and treatment of depression. J. Clin. Psychiatry (1998) 59:11-14.
13. DELGADO PL: Depression: the case for a monoamine deficiency. J. Clin. Psychiatry (2000) 61:7-11.
14. RESSLER KJ, NEMEROFF CB: Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress. Anxiety (2000) 12(Suppl. 1):2-19.
15. HIRSCHFELD RM: History and evolution of the monoamine hypothesis of depression. J. Clin. Psychiatry (2000) 61:4-6.
16. SZABO ST, BLIER P: Effect of the selective noradrenergic reuptake inhibitor reboxetine on the firing activity or noradrenaline and serotonin neurons. Eur. J. Neurosci. (2001) 13:2077-2087.
17. MASSANA J, MOLLER HJ, BURROWS GD et al.: Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder. Int. Clin. Psychopharmacol. (1999) 14:73-80.
18. SCHATZBERG AF: Clinical efficacy of reboxetine in major depression. J. Clin. Psychiatry (2000) 61:31-38.
19. VERSIANI M, AMIN M, CHOUINARD G: Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder. J. Clin. Psychopharmacol. (2000) 20:28-34.
20. DELGADO PL, CHARNEY DS, PRICE LH et al.: Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch. Gen. Psychiatry (1990) 47:411-418.
21. DELGADO PL, MILLER HL, SALOMON RM et al.: Monoamines and the mechanism of antidepressant action: effects of catecholamine depletion on mood of patients treated with antidepressants. Psychopharmacol. Bull. (1993) 29:389-396.
22. DELGADO PL, MILLER HL, SALOMON RM et al.: Tryptophandepletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant actions. Biol. Psychiatry (1999) 46:212-220.
23. MILLER HL, DELGADO PL, SALOMON RM et al.: Clinical and biochemical effects of catecholamine depletion on antidepressant-induced remission of depression. Arch. Gen. Psychiatry (1996) 53:117-128.
24. SPILLMANN MK, VAN DER DOES AJ, RANKIN MA et al.: Tryptophan depletion in SSRI-recovered depressed outpatients. Psychopharmacol. (2001) 155:123-127.
25. ANAND A, CHARNEY D: Norepinephrine dysfunction in depression. J. Clin. Psychiatry (2000) 61:16-24.
26. GARVEY MJ, TUASON VB: Urinary levels of 3-methoxy-4-hydroxyphenylglycol predict symptom severity in selected patients with unipolar depression. Psychiatry Res. (1996) 62:171-177.
27. RAUCOULES D, LEVY C, AZORIN JM et al.: Plasma levels of MHPG, HVA and total 5-HIAA in depression. Preliminary study. Encephale (1992) 18:611-616.
28. YATES M, LEAKE A, CANDY JM et al.: 5HT2 receptor changes in major depression. Biol. Psychiatry (1990) 27:489-496.
29. MANN JJ, HUANG YY, UNDERWOOD MD et al.: A serotonin transporter gent promoter polymorphism (5-HTTLPR) and prefrontal cortical binding in major depression and suicide. Arch. Gen. Psychiatry (2000) 57:729-738.
30. OWENS MJ, NEMEROFF CB: Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin. Chem. (1994) 40:288-295.
31. WOOD MD, THOMAS DR, WATSON JM: Therapeutic potential of serotonin antagonists in depressive disorders. Expert Opin. Investig. Drugs (2002) 11:457-467.
32. MASAND PS, GUPTA S: Selective serotonin-reuptake inhibitors: an update. Harv. Rev. Psychiatry (1999) 7:69-84.
33. BYMASTER FP, KATNER JS, NELSON DL et al.: Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: A potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology (2002) 27:699-711.
34. BYMASTER FP, ZHANG W, CARTER PA et al.: Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology (2002) 160:353-361.
35. NIBUYA M, MORINOBU S, DUMAN RS: Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J. Neurosci. (1995) 15:7539-7547.
36. NIBUYA M, NESTLER EJ, DUMAN RS: Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J. Neurosci. (1996) 16:2365-2372.
37. ANDERSON IM: SSRIs versus tricyclic antidepressants in depressed in patients: a meta-analysis of efficacy and tolerability. Depress. Anxiety (1998) 7(Suppl.):11-17.
38. BURKE WJ: Escitalopram. Expert Opin. Investig. Drugs (2002) 11:1477-1486.
39. HYTTEL J, BOGESO KP, PERREGAARD J et al.: The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer. J. Neural. Transm. Gen. Sect. (1992) 88:157-160.
40. OWENS MJ, KNIGHT DL, NEMEROFF CB: Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol. Psychiatry (2001) 50:345-350.
41. KOCH S, PERRY KW, NELSON DL et al.: R-fluoxetine increases extracellular DA, NE, as well as 5-HT in rat prefrontal cortex and hypothalamus: An in vivo microdialysis and receptor binding study. Neuropsychopharmacology (2002) 27:949-959.
42. 2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo. Neuropharmacology (1998) 37:953:955.
43. WONG EH, SONDERS MS, AMARA SG et al.: Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biol. Psychiatry (2000) 47:818-829.
44. SACCHETTI G, BERNINI M, BIANCHETTI A et al.: Studies on the acute and chronic effects of reboxetine on extracellular noradreanline and other monoamines in the rat brain. Br. J. Pharmacol. (1999) 128:1332-1338.
45. PAGE ME LUCKI I: Effects of acute and chronic reboxetine treatment on stress-induced monoamine efflux in the rat frontal cortex. Neuropsychopharmacology (2002) 27:237-247.
46. CARBONI E, TANDA GL, FRAU R et al.: Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals. J. Neurochem. (1990) 55:1067-1070.
47. MILLER DK, WONG EH, CHESNUT MD et al.: Reboxtine: functional inhibition of monoamine transporters and nicotinic acetylcholine receptors. J. Pharmacol. Exp. Ther. (2002) 302:687-695.
48. SCATES AC, DORAISWAMY PM: Reboxetine: a selective norepinephrine reuptake inhibitor for the treatment of depression. Ann. Pharmacother. (2000) 34:1302-1312.
49. MUCCI M: Reboxetine: a review of antidepressant tolerability. J. Psychopharmacol. (1997) 11(4, Suppl.):S33-S37.
50. ZERBE RL, ROWE H, ENAS GG et al.: Clinical pharmacology of tomoxetine, a potential antidepressant. J. Pharmacol. Exp. Ther. (1985) 232:139-143.
51. CHOUINARD G, ANNABLE L, BRADWEJN J: An early Phase II clinical trial of tomoxetine (LY139603) in the treatment of newly admitted depressed patients. Psychopharmacology (1984) 83:126-128.
52. SPENCER T, BIEDERMAN J, WILENS T et al.: Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am. J. Psychiatry (1998) 155:693-695.
53. MICHELSON D, FARIES D, WERNICKE J et al.: Atomoxetine in the treatment of children and adolescents with attention deficit/hyperactivity disorder: a roandomized, placebo-controlled, dose-response study. Pediatrics (2001) 108:E83.
54. TRAUT M, WEIFENBACH M, UNGER L: Biochemical studies on the potential antidepressant nafenodone, its enantiomers and its N-desmethylderivatives. Naunyn-Schmiedeberg's Arch. Pharmacol. (1991) (Suppl.):R110.
55. PEREZ-VIZCAINO F, CARRON R, DELPON E et al.: Effects of (S)-nafenodone, a new antidepressant, in isolated guinea-pig atrial and ventricular muscle fibers. Eur. J. Pharmacol. (1991) 199:43-50.
56. PEREZ-VIZCAINO F, CARRON R, DELPON E et al.: Effects of (S)-nafenodone on 45Ca2+ fluxes and contractions in rat isolated vascular smooth muscle. Eur. J. Pharmacol. (1993) 232:105-111.
57. JOBERT M, JAHNIG P, SCHULZ H: Effect of two antidepressant drugs on REM sleep and EMG activity during sleep. Neuropsychobiology (1999) 39:101-109.
58. TRAN P, BYMASTER F, MCNAMARA R et al.: Dual monoamine modulation for improved treatment of major depressive disorder. J. Clin. Psychopharmacology (2003) 23:78-86.
59. BOLDEN-WATSON C, RICHELSON E: Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci. (1993) 52:1023-1029.
60. BYMASTER FP, DRESHFIELD-AHMAD LJ, THRELKELD PG et al.: Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes and other neuronal receptors. Neuropsychopharmacology (2001) 25:871-880.
61. BRILEY M, PROST JF, MORET C: Preclinical pharmacology of milnacipran. Int. Clin. Psychopharmacol. (1996) 11:9-14.
62. BEL N, ARTIGAS F: Modulation of the extracellular 5-hydroxytryptamine brain concentrations by the serotonin and noradrenaline reuptake inhibitor, milnacipran. Microdialysis studies in rats. Neuropsychopharmacology (1999) 21:745-754.
63. LECRUBIER Y, PLETAN Y, SOLLES A et al.: Clinical efficacy of milnacipran in placebo-controlled trials. Int. Clin. Psychopharmacol. (1996) 11:29-33.
64. PUECH A, MONTGOMERY SA, PROST JF et al.: Milnacipran, a new sorotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability. Int. Clin. Psychopharmacol. (1997) 12:99-108.
65. WONG DT, BYMASTER FP: Dual serotonin and noradrenaline uptake inhibitor class of antidepressants - potential for greater efficacy or just hype? In: Progress in Drug Research (Vol. 58). E Jucker (Ed.) (2002):169-222.
66. GOLDSTEIN DJ, MALLINCKRODT C, LU Y et al.: Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J. Clin. Psychiatry (2002) 63:225-231.
67. DETKE MJ, LU Y, GOLDSTEIN DJ et al.: Duloxetine 60 mg once daily for major depressive disorder: a randomized double-blind placebo-controlled trial. J. Clin. Psychiatry (2002) 63:308-315.
68. DETKE MJ, LU Y, GOLDSTEIN DJ et al.: Duloxetine 60 mg once-daily dosing versus placebo in the acute treatment of major depression. J. Psychiatric Res. (2002) 36:383-390.
69. NEMEROFF C, SCHATZBERG A, GOLDSTEIN D et al.: Duloxetine for the treatment of major depressive disorder. Psychopharmacol. Bull. (2002) 36:105-132.
70. GOLDSTEIN DJ, LU Y, DETKE MJ et al.: Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J. Clin. Psychopharmacol.(In Press).
71. MILLAN MJ, GOBERT A, LEJEUNE F et al.: S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. J. Pharmacol. Exp. Ther. (2001) 298:565-580.
72. MILLAN MJ, GOBERT A, LEJEUNE F et al.: The novel, potential antidepressants, S35966 and S35967, act as serotonin and norepinephrine reuptake inhibitors and antagonists at alpha2-adrenoreceptors. Soc. Neurosci. Abst. (2001) 27:975.18.
73. MILLAN MJ, DEKEYNE A, PAPP M et al.: S33005, a novel ligand at both serotonin and norepinephrine transporters: II. Behavioral profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. J. Pharmacol. Exp. Ther. (2001) 298:581-591.
74. BROCCO M, DEKEYNE A, VEIGA S et al.: Induction of hyperlocomotion in mice exposed to a novel environment by inhibition of serotonin reuptake. A pharmacological characterization of diverse classes of antidepressant agents. Pharmacol. Biochem. Behav. (2002) 71:667-680.
75. KLIMEK V, SCHENCK J, HAN H et al.: Dopaminergic abnormalities in amygdaloid nuclei in major depression: a postmortem study. Biol. Psychiatry (2002) 52:740.
76. LAMBERT G, JOHANSSON M, AGREN H et al.: Reduced brain norepinephrine and dopamine release in treatment-refractory depressive illness: evidence in support of the catecholamine hypothesis of mood disorders. Arch. Gen. Psychiatry (2000) 57:787-793.
77. TREMBLAY LK, NARANJO CA, CARDENAS L et al.: Probing brain reward system function in major depressive disorder: altered response to dextroamphetamine. Arch. Gen. Psychiatry (2002) 59:409-416.
78. WILLNER P: The mesolimbic dopamine system as a target for rapid antidepressant action. Int. Clin. Psychopharmacol. (1997) 12(Suppl. 3):S7-S14.
79. DALERY J, ROCHAT C, PEYRON E et al.: The efficacy and acceptability of amineptine versus fluoxetine in major depression. Int. Clin. Psychopharmacol. (1997) 12(Suppl. 3):S35-S38.
80. KAVOUSSI RJ, SEGRAVES RT, HUGHES AR et al.: Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients. J. Clin. Psychiatry (1997) 58:532-537.
81. DEVEAUGH-GEISS J, CONNERS CK, SARKIS EH et al.: GW320659 for the treatment of attention-deficit/hyperactivity disorder in children. J. Am. Acad. Child Adolesc. Psychiatry (2002) 41:914-920.
82. BENNETT BA, WICHEMS CH, HOLLINGSWORTH CK et al.: Novel 2-substituted cocaine analogs: uptake and ligand binding studies at dopamine, serotonin and norepinephrine transport sites in the rat brain. J. Pharmacol. Exp. Ther. (1995) 272:1176-1186.
83. DAVIES HM, SAIKALI E, SEXTON T et al.: Novel 2-substituted cocaine analogs: binding properties at dopamine transport sites in rat striatum. Eur. J. Pharmacol. (1993) 244:93-97.
84. BENNETT BA, HOLLINGSWORTH CK, MARTIN RS et al.: Prolonged dopamine and serotonin transporter inhibition after exposure to tropanes. Neuropharmacology (1998) 37:123-730.
85. DAUNAIS JB, HART SL, SMITH HR et al.: Long-acting blockade of biogenic amine transporters in rat brain by administration of the potent novel tropane 2beta-propanoyl-3beta-(2-Naphthyl)-tropane. J. Pharmacol. Exp. Ther. (1998) 285:1246-1254.
86. ROBERTS DC, PHELAN R, HODGES LM et al.: Self-administration of cocaine analogs by rats. Psychopharmacology (1999) 144:389-397.
87. RYAN DH: Use of sibutramine and other noradrenergic and serotonergic drugs in the management of obesity. Endocrine (2000) 13:193-199.
88. GLICK SD, HASKEW RE, MAISONNEUVE IM et al.: Enantioselective behavioral effects of sibutramine metabolites. Eur. J. Pharmacol. (2000) 397:93-102.
89. FULTON B, BENFIELD P: Moclobemide. An update of its pharmacological properties and therapeutic use. Drugs (1996) 52:450-474.
90. MORON JA, PEREZ V, PASTO M et al.: FA-70, a novel selective and irreversible monoamine oxidase-A inhibitor: effect on monoamine metabolism in mouse cerebral cortex. J. Pharmacol. Exp. Ther. (2000) 292:788-794.
91. MORON JA, PEREZ V, FERNANDEZ-ALVAREZ E et al.: 'In vitro' effect of some 5-hydroxy-indolalkylamine derivatives on monoamine uptake system. J. Neural Transm. (1998) 52(Suppl.):343-349.
92. KRENITSKY PHARMACEUTICAL, INC.: In vivo (1996) 14:10.
93. KORSHUNOV VA, MURASHEV AN, IVASHEV MN et al.: Hemodynamic effects of tetrindol in alert normotensive mice and rats after blockade of nitric oxide synthesis. Bull. Exp. Biol. Med. (2000) 130:777-779.
94. RF279773: Tetrindol. Drugs Future (1997) 22(12).
95. BLIER P: Crosstalk between the norepinephrine and serotonin systems and its role in the antidepressant response. J. Psychiatry Neurosci. (2001) 26:S3-S10.
96. DE BOER T: The pharmacologic profile of mirtazapine. J. Clin. Psychiatry (1996) 57:19-25.
97. KASPER S: Clinical efficacy of mirtazapine: a review of meta-analyses of pooled data. Int. Clin. Psychopharmacol. (1995) 10:25-35.
98. QUITKIN FM, TAYLOR BP, KREMER C: Does mirtazapine have a more rapid onset than SSRIs? J. Clin. Psychiatry (2001) 62:358-361.
99. DAVIS R, WHITTINGTON R, BRYSON HM: Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression. Drugs (1997) 53:608-636.
100. BALDWIN DS, HAWLEY CJ, MELLORS K: CN104-070 Study Group: A randomized, double-blind controlled comparison of nefazodone and paroxetine in the treatment of depression: safety, tolerability and efficacy in continuation phase treatment. J. Psychopharmacol. (2001) 15:161-165.
101. ARTIGAS F: Limitations to enhancing the speed of onset of antidepressants - are rapid action antidepressants possible? Hum. Psychopharmacol. (2001) 16:29-36.
102. ZHANG W, PERRY KW, WONG DT et al.: Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology (2000) 23:250-262.
103. SHELTON RC, TOLLEFSON GD, TOHEN M et al.: A novel augmentation strategy for treating resistant major depression. Am. J. Psychiatry (2001) 158:131-134.
104. BAKER RW, VIETA E, KETTER TA et al.: Olanzapine and olanzapine-fluoxetine combination (OFC) in the treatment of bipolar depression. Abstr. Am. College Neuropsychopharmacol. Ann. Meeting (2002):220.
105. PULLAR IA, BOOT JR, CARNEY SL et al.: In vitro activity of LY393558, an inhibitor of the 5-hydroxytryptamine transporter with 5-HT(1B/1D/2) receptor antagonist properties. Eur. J. Pharmacol. (2001) 432:9-17.
106. MITCHELL SN, GREENSLADE RG, COOPER J: LY393558, a 5-hydroxytryptamine reuptake inhibitor and 5-HT(1B/1D) receptor antagonist: effects on extracellular levels of 5-hydroxytryptamine in the guinea pig and rat. Eur. J. Pharmacol. (2001) 432:19-27.
107. PULLAR IA, CARNEY SL, COLVIN EM et al.: LY367265, an inhibitor of the 5-hydroxytryptamine transporter and 5-hydroxytryptamine(2A) receptor antagonist: a comparison with the antidepressant, nefazodone. Eur. J. Pharmacol. (2000) 407:39-46.
108. TORDERA RM, MONGE A, DEL RIO J et al.: VN-2222, a potential antidepressant agent with affinity at the serotonin transporter and 5-HT1A receptors. Meth. Find. Exp. Clin. Pharmacol. (1999) 21(Suppl. A):197.
109. TORDERA RM, MONGE A, DEL RIO J et al.: Antidepressant-like activity of VN2222, a serotonin reuptake inhibitor with high affinity at 5-HT1A receptors. Eur. J. Pharmacol. (2002) 442:63-71.
110. BARTOSZYK GD, HEGENBART R, ZIEGLER H: EMD 68843, a serotonin reuptake inhibitor with selective presynaptic 5-HT1A receptor agonistic properties. Eur. J. Pharmacol. (1997) 322:147-153.
111. PAGE ME, CRYAN JF, SULLIVAN A et al.: Behavioral and neurochemical effects of 5-(4-[4-(5-Cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl)-benzofuran-2- carboxamide (EMD 68843): a combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine(1A) receptor partial agonist. J. Pharmacol. Exp. Ther. (2002) 302:1220-1277.
112. TREIT D, DEGROOT A, KASHLUBA S et al.: Systemic EMD 68843 injections reduce anxiety in the shock-probe, but not the plus-maze test. Eur. J. Pharmacol. (2001) 414:245-248.
113. CORDI AA, BERQUE-BESTEL I, PERSIGAND T et al.: Potential antidepressants displayed combined alpha(2)-adrenoceptor antagonist and monoamine uptake inhibitor properties. J. Med. Chem. (2001) 44:787-805.
114. MCKINNON C: Summary of medicinal chemistry 16th international symposium, Bologna, Italy. IDdb Meeting Report (2000).
115. CORDI A, BERQUE-BESTEL I, PERSIGAND T et al.: Search for novel antidepressants through synergy between alpha2 adrenoreceptor antagonism and monoamine uptake inhibition. Int. Symp. Med. Chem. (2000):PB 57.
116. LUCKI I, SINGH A, KREISS DS: Antidepressant-like behavioral effects of serotonin receptor agonists. Neurosci. Biobehav. Rev. (1994) 18:85-95.
117. LUSCOMBE GP, MARTIN KF, HUTCHINS LJ et al.: Mediation of the antidepressant-like effect of 8-OH-DPAT in mice by postsynaptic 5-HT1A receptors. Br. J. Pharmacol. (1993) 108:669-677.
118. FEIGER AD: A double-blind comparison of gepirone extended release, imipramine, and placebo in the treatment of outpatient major depression. Psychopharmacol. Bull. (1996) 32:659-665.
119. WILCOX CS, FERGUSON JM, DALE JL et al.: A double-blind trial of low- and high-dose ranges of gepirone-ER compared with placebo in the treatment of depressed outpatients. Psychopharmacol. Bull. (1996) 32:335-342.
120. TOTTORI K, MIWA T, UWAHODO Y et al.: Antidepressant-like responses to the combined sigma and 5-HT1A receptor agonist OPC-14523. Neuropharmacology (2001) 41:976-988.
121. TOTTORI K, NAKAI M, UWAHODO Y et al.: Attenuation of scopolamine-induced and age-associated memory impairments by the sigma and 5-hydroxytryptamine(1A) receptor agonist OPC-14523 (1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-methoxy-3,4-dihydro- 2[1H]-quinolinone monomethanesulfonate). J. Pharmacol. Exp. Ther. (2002) 301:249-257.
122. PIERCY MF: Pharmacology of pramipexole, a dopamine D3-preferring agonist, useful in treating Parkinson's disease. Clin. Neuropharmacol. (1998) 21:141-151.
123. WILLNER P, LAPPAS S, CHEETA S et al.: Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole. Psychopharmacology (1994) 115:454-462.
124. CORRIGAN MH, DENAHAN AQ, WRIGHT CE et al.: Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress. Anxiety (2000) 11:58-65.
125. NEWMAN-TANCREDI A, CUSSAC D, AUDINOT V et al.: Actions of roxindole at recombinant human dopamine D2, D3 and D4 and serotonin 5-HT1A, 5-HT1B and 5-HT1D receptors. Naunyn Schmiedebergs Arch. Pharmacol. (1999) 359:447-453.
126. MAJ J, KOLODZIEJCZYK K, ROGOZ Z, SKUZA G: Roxindole, a potential antidepressant. I. Effect on the dopamine system. J. Neural Transm. Gen. Sect. (1996) 103:627-641.
127. GRUNDER G, WETZEL H, HAMMES E et al.: Roxindole, a dopamine autoreceptor agonist, in the treatment of major depression. Psychopharmacology (1993) 111:123-126.
128. TATSUMI M, GROSHAN K, BLAKELY RD et al.: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur. J. Pharmacol. (1997) 340:249-258.
129. OWENS MJ, MORGAN WN, PLOTT SJ et al.: Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J. Pharmacol. Exp. Ther. (1997) 283:1305-1322.
130. MILLAN MJ, GOBERT A, RIVET JM et al.: Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram. Eur. J. Neurosci. (2000) 12:1079-1095.